How will you decide between mFOLFIRINOX vs gemcitabine+capecitabine for resected pancreatic cancer patients?

Can you comment based on the results of PRODIGE 24 from ASCO 2018? http://abstracts.asco.org/214/AbstView_214_218335.html

Community PollStarted

What adjuvant regimen would you use for resected pancreatic cancer patients?

86 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet MemberInvited Expert

Medical Oncology · Stanford University School of Medicine

Answered on

The results of the PRODIGE-24 trial are among the most significant of the last quarter century in terms of their impact on the treatment of patients with pancreatic adenocarcinoma. The administration of mFOLFIRINOX resulted in almost a doubling of 3 yr DFS (the primary endpoint) and also extended th...

Join for free or sign in to see the full answer